Advanced search: Search from
Select basic information for advanced search
| Free word |
|---|
Rchr
J-GLOBAL ID：201601014826682536
Update date: Feb. 17, 2025 Oyanagi Jun
オヤナギ ジュン | Oyanagi Jun
- 2021 - 2024 Elucidation of synergistic mechanisms in the combination of chemotherapy and PD-1/L1 inhibitors and exploration for novel therapeutic targets
- 2019 - 2022 Basic Research Toward Precision Medicine Using Human Lung Cancer Organoids
- 2016 - 2018 Role of Kras mutations in intestinal tumor progression
- Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Satoru Miura, Hidetoshi Hayashi, Akito Hata, Yukihiro Toi, Yoshimasa Shiraishi, Nobuaki Mamesaya, Yuki Sato, et al. Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. OF1-OF7
- 小澤 雄一, 春谷 勇平, 小柳 潤, 赤松 弘朗, 村上 恵理子, 佐藤 孝一, 柴木 亮太, 杉本 武哉, 早田 敦志, 寺岡 俊輔, et al. 腫瘍におけるcGAS及びSTING発現と非小細胞肺癌におけるPD-1/L1阻害剤の有効性及び血清サイトカインとの関連. 日本呼吸器学会誌. 2022. 11. 増刊. 227-227
- Yuhei Harutani, Yuichi Ozawa, Eriko Murakami, Koichi Sato, Jun Oyanagi, Hiroaki Akamatsu, Takanori Yoshikawa, Ryota Shibaki, Takeya Sugimoto, Katsuyuki Furuta, et al. Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors. Cancer immunology, immunotherapy : CII. 2022. 71. 9. 2109-2116
- Jun Oyanagi, Yasuhiro Koh, Koichi Sato, Shunsuke Teraoka, Nahomi Tokudome, Atsushi Hayata, Hiroaki Akamatsu, Yuichi Ozawa, Masanori Nakanishi, Hiroki Ueda, et al. Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors. Clinical lung cancer. 2021. 22. 6. e833-e841
- 小柳 潤, 洪 泰浩, 佐藤 孝一, 杉本 武哉, 柴木 亮太, 寺岡 俊輔, 藤本 大智, 徳留 なほみ, 早田 敦志, 小澤 雄一, et al. 進行性胸部悪性腫瘍患者由来オルガノイドの樹立(Establishment of organoids derived from patients with advanced thoracic malignancies). 肺癌. 2021. 61. 6. 682-682
- 小柳 潤, 洪 泰浩, 佐藤 孝一, 杉本 武哉, 柴木 亮太, 寺岡 俊輔, 藤本 大智, 徳留 なほみ, 早田 敦志, 小澤 雄一, et al. Establishment of organoids derived from patients with advanced thoracic malignancies(和訳中). 肺癌. 2021. 61. 6. 682-682
- 小柳 潤, 洪 泰浩, 佐藤 孝一, 赤松 弘朗, 上田 弘樹, 山本 信之. 胸部原発悪性腫瘍患者由来オルガノイドの樹立. 日本癌学会総会記事. 2021. 80回. [J14-5]
- 小澤 雄一, 春谷 勇平, 小柳 潤, 村上 恵理子, 赤松 弘朗, 早田 篤志, 上田 弘樹, 中西 正典, 洪 泰浩, 山本 信之. CD24及びCD47腫瘍発現とPD-1/L1阻害剤の有効性及び投与後サイトカイン変動との関連. 和歌山医学. 2021. 72. 1. 42-42
- 小柳 潤, 洪 泰浩, 佐藤 孝一, 赤松 弘朗, 上田 弘樹, 山本 信之. 進行非小細胞肺癌患者における免疫チェックポイント阻害剤治療の臨床効果予測バイオマーカーの探索. 日本癌学会総会記事. 2020. 79回. OJ12-1
- 小柳 潤, 洪 泰浩, 佐藤 孝一, 寺岡 俊輔, 徳留 なほみ, 早田 敦志, 赤松 弘朗, 小澤 雄一, 中西 正典, 上田 弘樹, et al. 免疫チェックポイント阻害薬で治療した進行性NSCLCにおける血清タンパク質の複合分析(Combined analysis of serum proteins in advanced NSCLC treated with immune checkpoint inhibitors). 肺癌. 2020. 60. 6. 532-532
-
Establishment of organoids derived from patients with advanced thoracic malignancies
(2021) -
Establishment of organoids derived from patients with advanced thoracic malignancies
(2021) -
Combined analysis of serum proteins in advanced NSCLC treated with immune checkpoint inhibitors
(2020) -
Combined analysis of serum protein levels in advanced NSCLC patients treated with immune checkpoint inhibitors
(2020) -
Predictive Values of Serum Protein Levels in Advanced NSCLC Patients Treated with Pembrolizumab
(2019)
- 2010 - 2013 Yokohama City University Graduate Graduate School of Nanobioscience
- 2008 - 2010 Yokohama City University Graduate
- 博士(理学) (横浜市立大学)
- 2022/12 - 現在 Texas A&M University Senior Research Scientist
- 2021/04 - 2022/07 Wakayama Medical University
- 2017/04 - 2021/03 Wakayama Medical University
- 2013/04 - 2017/03 Japanese Foundation for Cancer Research
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.
Return to Previous Page
